Clinical Course, Imaging Characteristics, and Therapeutic Response in Myelin Oligodendrocyte Glycoprotein Antibody Disease: A Case Series.
India
magnetic resonance imaging
myelin oligodendrocyte glycoprotein
neuromyelitis optica
rituximab
Journal
Journal of neurosciences in rural practice
ISSN: 0976-3147
Titre abrégé: J Neurosci Rural Pract
Pays: United States
ID NLM: 101533710
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
entrez:
7
3
2020
pubmed:
7
3
2020
medline:
7
3
2020
Statut:
ppublish
Résumé
Myelin oligodendrocyte glycoprotein (MOG) antibody disease is a novel central nervous system autoimmune disorder which forms part of aquaporin 4 (AQP-4) negative, neuromyelitis optica (NMO) spectrum disorder. It has a distinct clinical profile, neuroimaging features and courses from AQP-4 positive NMO and multiple sclerosis. This article is a case series of six patients with MOG antibody disease with longitudinal follow-up for up to 8 months.
Identifiants
pubmed: 32140030
doi: 10.1055/s-0040-1701371
pii: JNRP190122
pmc: PMC7055612
doi:
Types de publication
Journal Article
Langues
eng
Pagination
205-210Déclaration de conflit d'intérêts
Conflict of Interest None declared.
Références
Brain. 2017 Dec 1;140(12):3128-3138
pubmed: 29136091
Arch Neurol. 2012 Sep;69(9):1176-80
pubmed: 22733096
Ann Indian Acad Neurol. 2017 Oct-Dec;20(4):411-413
pubmed: 29184347
J Neurol. 2017 Oct;264(10):2173-2175
pubmed: 28914353
Pract Neurol. 2019 Jun;19(3):187-195
pubmed: 30530724
JAMA Neurol. 2014 Mar;71(3):276-83
pubmed: 24425068
J Neurochem. 1989 Jan;52(1):296-304
pubmed: 2462020
J Neurochem. 1999 Jan;72(1):1-9
pubmed: 9886048
Ann Indian Acad Neurol. 2016 Oct-Dec;19(4):505-509
pubmed: 27994362
Front Immunol. 2017 May 08;8:529
pubmed: 28533781
Neurol Neuroimmunol Neuroinflamm. 2015 Mar 19;2(3):e89
pubmed: 25821844
Neurology. 2018 May 22;90(21):e1858-e1869
pubmed: 29695592
Glia. 2001 Nov;36(2):220-34
pubmed: 11596130